You are here
Myriad Genetics to Present Five Studies at the Seventh International Symposium on Hereditary Breast and Ovarian Cancer
Presentations Highlight Continued Advancements in Hereditary Cancer Testing
SALT LAKE CITY, May 04, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from five studies at the Seventh International Symposium on Hereditary Breast and Ovarian Cancer annual meeting to be held May 8 to 11, 2018 in Montréal, Canada. More information about the symposium can be found here: http://www.brcasymposium.ca/
“We look forward to presenting important new research on risk associated with breast and ovarian cancer gene mutations,” said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetics. “Our presentations will highlight Myriad’s ongoing commitment to research, advances to state-of-the-art hereditary cancer risk assessment and the highest quality of clinical testing.”
A list of Myriad presentations at the symposium is below. Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #BRCASYMP.
|Pheno Analysis Is a Highly Accurate and|
Robust Variant Classification Algorithm with
High Tolerance for Reported Clinical History
May 9, 2018:
|Performance of Current Hereditary Breast and|
Ovarian Cancer (HBOC) Testing Criteria for The
Detection of Carriers of Pathogenic Variants in
Clinically Significant Breast Cancer Risk Genes
Other Than BRCA1/2
May 9, 2018:
|Comparison of Cancer Risks in Truncating vs.|
Missense CHEK2 Pathogenic Variants
|Erin Mundt||Poster PO97|
May 9, 2018:
|Development and Validation of a Combined|
Residual Risk Score to Predict Breast Cancer
Risk in Unaffected Women Negative for
Mutations on a Multi-Gene Hereditary Cancer
May 9, 2018:
|Families with a Known Mutation in a Cancer|
Predisposition Gene: Is Single Site Testing
Always the Best Option for Relatives?
May 9, 2018:
About Myriad myRisk® Hereditary Cancer
The Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms in an 850 step laboratory process to evaluate 28 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma. For more information visit: https://www.myriad.com/products-services/hereditary-cancers/myrisk-hereditary-cancer/.
riskScore is a clinically validated personalized medicine tool that enhances Myriad's myRisk® Hereditary Cancer test. riskScore helps to further predict a women's lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome. The test incorporates data from greater than 80 single nucleotide polymorphisms identified through 20 years of genome wide association studies in breast cancer and was validated in our laboratory to predict breast cancer risk in women of European descent. This data is then combined with a best-in-class family and personal history algorithm, the Tyrer-Cuzick model, to provide more patients with individualized breast cancer risk.
About Myriad Genetics
Myriad Genetics Inc. is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to data being presented at the at the Seventh International Symposium on Hereditary Breast and Ovarian Cancer annual meeting to be held May 8 to 11, 2018 in Montréal, Canada and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
|Media Contact:||Ron Rogers||Investor Contact:||Scott Gleason|
|(801) 584-3065||(801) 584-1143|